Literature DB >> 23410792

Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials.

Dennis A K Rice1, Koné Kaniga, Michael Lee, Rebecca Redman.   

Abstract

An analysis of subjects with concurrent bacteraemia and either nosocomial pneumonia, complicated intra-abdominal infection or complicated urinary tract infection from six phase 3 clinical trials demonstrated similar cure rates and clearance of bacteraemia in patients treated with doripenem and comparator agents.
Copyright © 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23410792     DOI: 10.1016/j.ijantimicag.2012.12.016

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  3 in total

1.  The doripenem serum concentrations in intensive care patients suffering from acute kidney injury, sepsis, and multi organ dysfunction syndrome undergoing continuous renal replacement therapy slow low-efficiency dialysis.

Authors:  Andrzej Wieczorek; Andrzej Tokarz; Wojciech Gaszynski; Tomasz Gaszynski
Journal:  Drug Des Devel Ther       Date:  2014-10-23       Impact factor: 4.162

2.  In vitro Antibacterial Activity of Doripenem against Gram-Negative Blood Isolates in a Korean Tertiary Care Center.

Authors:  Seong-Ho Choi; Mi Young Ahn; Jin-Won Chung; Mi-Kyung Lee
Journal:  Infect Chemother       Date:  2015-09-30

3.  A meta-analysis of efficacy and safety of doripenem for treating bacterial infections.

Authors:  Xiao-Yu Qu; Ting-Ting Hu; Wei Zhou
Journal:  Braz J Infect Dis       Date:  2015-01-27       Impact factor: 3.257

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.